Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBT 031

Drug Profile

BBT 031

Alternative Names: BBT-031; Long-acting PEGylated somatropin - Bolder BioTechnology; PEG-GH - Bolder BioTechnology; PEG-growth hormone - Bolder BioTechnology; Pegylated-growth hormone - Bolder BioTechnology; Pegylated-somatropin - Bolder BioTechnology

Latest Information Update: 19 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bolder BioTechnology
  • Class Growth hormones; Hormonal replacements; Polyethylene glycols
  • Mechanism of Action Human growth hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Somatotropin deficiency
  • Discontinued Lipodystrophy; Short stature

Most Recent Events

  • 19 Jun 2023 BBT 031 is still in preclinical development for Somatotropin-deficiency in USA (Parenteral) (Bolder Biotechnology pipeline, June 2023)
  • 28 May 2022 No recent reports of development identified for preclinical development in Somatotropin-deficiency in USA (Parenteral, Injection)
  • 20 May 2020 BBT 031 is available for licensing as of 20 May 2020. http://www.bolderbio.com/
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top